Skip to main content

Month: June 2024

Pineapple Express Cannabis Company Executes Substantial Revenue Generating Contract Regarding Multiple Cannabis Dispensaries

Company signs contract to receive 5% of all sales at 7 retail dispensaries in Los Angeles LOS ANGELES, CA, June 11, 2024 (GLOBE NEWSWIRE) — Pineapple Express Cannabis Company (OTC: PNXP) (the “Company” or “Pineapple Express”), a publicly traded company, today announced that its wholly owned subsidiary, Ananas Growth Ventures (“AGV”), has signed a revenue generating contract with Pineapple Consolidated, Inc. to receive 50% of its management fee revenue related to multiple legal cannabis retail operations in Los Angeles, in exchange for a $5 million-dollar promissory note. The contract, which has been in the works for weeks, is effective as of April 20, 2024, but was ratified by the board of directors of the Company and signed on June 10, 2024. The deal involves operational and to be operational retail dispensaries in Hollywood,...

Continue reading

Candel Therapeutics to Join Russell 3000® Index

NEEDHAM, Mass., June 11, 2024 (GLOBE NEWSWIRE) — Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that the Company is set to join the broad-market Russell 3000 Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1, 2024, according to a preliminary list of additions posted Friday, May 24, 2024. The annual Russell US Indexes reconstitution captures the 4,000 largest US stocks as of Tuesday, April 30th, ranking them by total market capitalization. Membership in the US all-cap Russell 3000® Index, which remains in place for one year, means automatic inclusion in the large-cap Russell...

Continue reading

Bebuzee, Inc. Unveils New and Exciting Live Streaming Features in Its Revolutionary Super App

MIAMI, June 11, 2024 (GLOBE NEWSWIRE) — via IBN – Bebuzee, Inc. (OTC: BBUZ), a leading social media and digital entertainment platform, is thrilled to announce the launch of two groundbreaking live streaming features in its revolutionary super app. These innovative additions are designed to enhance user engagement and transform the digital experience for millions of Bebuzee users worldwide. Introducing Live Streaming: TikTok- and YouTube-Style Experiences Bebuzee is excited to introduce live streaming features that offer unique and captivating experiences, similar to content shared via TikTok and YouTube. These new, inspired features are set to redefine how users experiment with content and connect with their favorite creators and communities. TikTok-Style Live Streaming Our TikTok-style live streaming feature allows users to broadcast...

Continue reading

Kratos Launches New Podcast to Help Businesses Navigate Their Cyber Compliance Journey

SAN DIEGO, June 11, 2024 (GLOBE NEWSWIRE) — In today’s hyper-connected world, businesses must comply with strict cybersecurity measures to operate and compete, especially for winning government contracts and in regulated industries. Misunderstanding the requirements or making mistakes during the certification process can result in fines, revenue loss, and even ineligibility to compete. To guide businesses to the right answers, Kratos Defense & Security Solutions (Nasdaq: KTOS) has launched a cybersecurity compliance podcast to help businesses set and achieve their compliance goals. For more than a decade Kratos has been a trusted cybersecurity compliance advisor and assessor supporting many of the world’s largest and most respected technology companies as well as mid-sized product makers and service providers. “Cyber Compliance...

Continue reading

Biora Therapeutics Announces Presentation on the BioJet™ Systemic Oral Delivery Platform at the Next Gen Peptide Formulation & Delivery Summit 2024

SAN DIEGO, June 11, 2024 (GLOBE NEWSWIRE) — Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it will present preclinical data from the BioJet™ Systemic Oral Delivery Platform at the Next Gen Peptide Formulation & Delivery Summit, which will take place June 18–20, 2024 in Boston. Details of the presentation are as follows:Presentation Title: Empowering Peptide Self Administration with Needle-Free Smart CapsulesTrack:  Pioneering Devices to Increase the Reach of Peptide APIsDate & Time: Wednesday, June 19, 2024 from 2:15 to 2:45 PM Eastern timePresenting Author: Sharat Singh, PhD, Head of Research, Biora Therapeutics, Inc.Dr. Singh will also participate in a panel discussion on June 19 at 8:45 AM titled “Uncovering Innovations...

Continue reading

TRACON Announces Publication in Clinical Cancer Research of Phase 2 Clinical Data for TRC102, a DNA Damage Repair Inhibitor, in Recurrent Glioblastoma Patients

Publication Highlights Activity of the Combination of TRC102 and Temodar (Temozolomide) in Patients who Progressed Following Initial Treatment with Surgical Resection, Temodar and External Beam Radiotherapy Consistent with the TRC102 Mechanism of Action, Extended Survival was Demonstrated in Patients with Activation of DNA Damage Response Pathways Prior to TRC102 Treatment SAN DIEGO, June 11, 2024 (GLOBE NEWSWIRE) — TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent Product Development Platform (PDP) to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, today announced the publication of Phase 2 clinical data of its DNA damage repair inhibitor drug candidate, TRC102, in patients with glioblastoma...

Continue reading

Apica Delivers Unmatched Data Management Capabilities with Additions to Ascent Platform

Apica Ascent platform 2.0 helps customers tame velocity, volume, variety, and sprawl for observability, machine, and operational data STOCKHOLM and EL SEGUNDO, Calif. , June 11, 2024 (GLOBE NEWSWIRE) — Apica, the leader in data management and active observability, today announced new capabilities for its Apica Ascent Platform. Following the company’s acquisitions of data fabric innovator LOGIQ.AI and telemetry data management pioneer Circonus, Apica has integrated capabilities from both organizations into its platform to provide deeper insights into data management. This makes it easier for customers to gather the needed data and seamlessly apply it to their systems and platforms. In addition to making two acquisitions over the last 10 months, Apica announced $16M in new capital. With this funding, it expanded its Office of the...

Continue reading

60 Degrees Pharmaceuticals Receives FDA Orphan Drug Designation for Tafenoquine for Treatment of Patients with Acute Babesiosis

With the tafenoquine for acute babesiosis orphan drug designation, 60 Degrees Pharmaceuticals now qualifies for certain incentives, including market exclusivity, tax credits, and exemption from certain FDA filing fees. 60 Degrees Pharmaceuticals recently announced it has entered into an agreement with Tufts Medical Center in Boston to conduct the world’s first clinical trial evaluating the efficacy and safety of tafenoquine in treating human babesiosis patients. FDA orphan drug designation is granted for therapeutic candidates that may prevent or treat a rare disease or condition, such as acute babesiosis.WASHINGTON, June 11, 2024 (GLOBE NEWSWIRE) — 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the “Company” or “60 Degrees Pharmaceuticals”), a pharmaceutical company focused on developing new medicines for infectious...

Continue reading

Fairfax Announces Termination of Total Return Swaps of Ensign Energy Services Inc. and Acquisition of Common Shares

TORONTO, June 11, 2024 (GLOBE NEWSWIRE) — Fairfax Financial Holdings Limited (“Fairfax”) (TSX: FFH and FFH.U) announces that on June 10, 2024, it terminated total return swaps over 7,787,600 common shares (“Common Shares”) of Ensign Energy Services Inc. (“Ensign”), which had an average reference price of C$1.3182. Upon the termination of the total return swaps, Fairfax agreed with the counterparty to purchase 7,787,600 Common Shares at a price of C$2.34 per Common Share, representing 4.24% of the outstanding Common Shares. Prior to the acquisition of the Common Shares, Fairfax beneficially owned and controlled 21,800,886 of the issued and outstanding Common Shares, representing approximately 11.86% of all issued and outstanding Common Shares. Following the acquisition of the Common Shares, Fairfax beneficially owns and controls...

Continue reading

Treasure Global Announces 113.5% Growth in Transactions for TAZTE, its Innovative Digital F&B Management System

Projected Market for Mobile POS Payments in Malaysia to Reach US$10.04 Billion by 2028* NEW YORK and KUALA LUMPUR, Malaysia, June 11, 2024 (GLOBE NEWSWIRE) — Treasure Global Inc (NASDAQ: TGL) (“Treasure Global” or the “Company”), an innovative technology solutions provider, is pleased to announce that TAZTE Smart F&B system (“TAZTE”), its innovative digital food and beverage (“F&B”) management system, continues to make significant strides in its development and market penetration. Transaction Growth and User EngagementTAZTE has shown impressive year-over-year growth in both transactions and user engagement. Without any additional marketing funds, the total number of transactions reached 7,540, marking a 113.5% increase. Additionally, the number of monthly transacted users rose by 55%, now totalling 3,752. These figures...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.